PMID- 22986611
OWN - NLM
STAT- MEDLINE
DCOM- 20130322
LR  - 20151119
IS  - 1538-2990 (Electronic)
IS  - 0002-9629 (Linking)
VI  - 345
IP  - 2
DP  - 2013 Feb
TI  - A retrospective analysis of cytogenetic and clinical characteristics in patients 
      with multiple myeloma.
PG  - 88-93
LID - 10.1097/MAJ.0b013e31825b32bc [doi]
AB  - BACKGROUND: Cytogenetic alterations in patients with multiple myeloma (MM) 
      represent important risk factors in terms of prognosis. In this study, the impact 
      of the cytogenetic aberrations of MM on patient clinical features and outcome was 
      investigated. METHODS: Conventional cytogenetic analysis with R-banding technique 
      and molecular cytogenetic characterization by interphase fluorescence in situ 
      hybridization (FISH) were used to detect aberrant chromosomal arrangements, 
      including 17p13 and 13q14 deletions, 14q32 rearrangement and 1q21 amplification, 
      in bone marrow nucleated cells from 65 patients. RESULTS: About 16.9% of patients 
      showed aberrations by conventional cytogenetic analysis, whereas 49.2% of 
      patients showed aberrations by interphase FISH analysis. Abnormalities of 13q14, 
      1q21, 14q32 and 17p13 were detected in 27.7%, 13.8%, 16.9% and 29.2%, 
      respectively. Patients with a 13q14 deletion or combined with 17p13 deletion 
      frequently had a late stage of the disease, and tended to have elevated serum 
      levels of beta2 microglobulin and lower levels of albumin. The progression-free 
      survival and overall survival of FISH-positive patients were lower than for those 
      without detectable abnormalities, especially in the conventional chemotherapy 
      arm. CONCLUSIONS: These findings demonstrate that myeloma cells are prone to 
      exhibiting a complex aberration and that FISH is superior to conventional 
      cytogenetic analysis with a higher detection rate of chromosomal abnormalities. 
      Patients with a 17p13 or 13q14 deletion, 14q32 rearrangement and 1q21 
      amplification were more likely to have a poor prognosis for MM.
FAU - He, Jingsong
AU  - He J
AD  - Multiple Myeloma Treatment Center and Department of Hematology, the First 
      Affiliated Hospital of Medical College, Zhejiang University, Hangzhou, China.
FAU - Yang, Li
AU  - Yang L
FAU - Meng, Xiaojian
AU  - Meng X
FAU - Wei, Guoqing
AU  - Wei G
FAU - Wu, Wenjun
AU  - Wu W
FAU - Han, Xiaoyan
AU  - Han X
FAU - Zheng, Gaofeng
AU  - Zheng G
FAU - Zheng, Weiyan
AU  - Zheng W
FAU - Ye, Xiujing
AU  - Ye X
FAU - Shi, Jimin
AU  - Shi J
FAU - Xie, Wanzhuo
AU  - Xie W
FAU - Zhang, Jie
AU  - Zhang J
FAU - Huang, He
AU  - Huang H
FAU - Lin, Maofang
AU  - Lin M
FAU - Cai, Zhen
AU  - Cai Z
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Med Sci
JT  - The American journal of the medical sciences
JID - 0370506
RN  - 0 (Boronic Acids)
RN  - 0 (Pyrazines)
RN  - 69G8BD63PP (Bortezomib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Boronic Acids/therapeutic use
MH  - Bortezomib
MH  - *Chromosome Aberrations
MH  - Cytogenetic Analysis/*methods
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/*diagnosis/drug therapy/*genetics
MH  - Pyrazines/therapeutic use
MH  - Retrospective Studies
EDAT- 2012/09/19 06:00
MHDA- 2013/03/23 06:00
CRDT- 2012/09/19 06:00
PHST- 2012/09/19 06:00 [entrez]
PHST- 2012/09/19 06:00 [pubmed]
PHST- 2013/03/23 06:00 [medline]
AID - S0002-9629(15)30732-1 [pii]
AID - 10.1097/MAJ.0b013e31825b32bc [doi]
PST - ppublish
SO  - Am J Med Sci. 2013 Feb;345(2):88-93. doi: 10.1097/MAJ.0b013e31825b32bc.